Alimera Sciences, Inc. (ALIM): Price and Financial Metrics
ALIM Price/Volume Stats
Current price | $3.90 | 52-week high | $4.38 |
Prev. close | $3.90 | 52-week low | $1.56 |
Day low | $3.76 | Volume | 57,600 |
Day high | $4.01 | Avg. volume | 82,787 |
50-day MA | $3.78 | Dividend yield | N/A |
200-day MA | $3.45 | Market Cap | 204.18M |
ALIM Stock Price Chart Interactive Chart >
ALIM POWR Grades
- Growth is the dimension where ALIM ranks best; there it ranks ahead of 99.07% of US stocks.
- ALIM's strongest trending metric is Quality; it's been moving down over the last 173 days.
- ALIM ranks lowest in Quality; there it ranks in the 16th percentile.
ALIM Stock Summary
- Equity multiplier, or assets relative to shareholders' equity, comes in at 7.23 for ALIMERA SCIENCES INC; that's greater than it is for 84.33% of US stocks.
- With a year-over-year growth in debt of 45.95%, ALIMERA SCIENCES INC's debt growth rate surpasses 86% of about US stocks.
- Revenue growth over the past 12 months for ALIMERA SCIENCES INC comes in at 26.67%, a number that bests 82.72% of the US stocks we're tracking.
- Stocks that are quantitatively similar to ALIM, based on their financial statements, market capitalization, and price volatility, are CMTL, FMC, ENVA, TWOU, and AGCO.
- ALIM's SEC filings can be seen here. And to visit ALIMERA SCIENCES INC's official web site, go to www.alimerasciences.com.
ALIM Valuation Summary
- In comparison to the median Healthcare stock, ALIM's price/earnings ratio is 136.36% lower, now standing at -10.6.
- Over the past 167 months, ALIM's EV/EBIT ratio has gone down 10.1.
Below are key valuation metrics over time for ALIM.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ALIM | 2023-12-29 | 3.3 | 4.6 | -10.6 | -21.7 |
ALIM | 2023-12-28 | 3.0 | 4.2 | -9.5 | -20.0 |
ALIM | 2023-12-27 | 2.9 | 4.1 | -9.4 | -19.9 |
ALIM | 2023-12-26 | 2.9 | 4.1 | -9.3 | -19.7 |
ALIM | 2023-12-22 | 3.0 | 4.1 | -9.5 | -19.9 |
ALIM | 2023-12-21 | 2.9 | 4.0 | -9.2 | -19.5 |
ALIM Growth Metrics
- Its 5 year cash and equivalents growth rate is now at -54.15%.
- Its year over year revenue growth rate is now at 25.71%.
- Its 3 year price growth rate is now at -71.58%.
The table below shows ALIM's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 54.059 | -14.407 | -18.433 |
2022-06-30 | 52.614 | -15.226 | -17.359 |
2022-03-31 | 59.713 | -6.936 | -6.679 |
2021-12-31 | 59.029 | -3.224 | -4.372 |
2021-09-30 | 58.844 | 1.196 | -1.243 |
2021-06-30 | 59.164 | 1.78 | 2.322 |
ALIM Price Target
For more insight on analysts targets of ALIM, see our ALIM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $14.83 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Alimera Sciences, Inc. (ALIM) Company Bio
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, the United Kingdom, and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through direct sales and distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Latest ALIM News From Around the Web
Below are the latest news stories about ALIMERA SCIENCES INC that investors may wish to consider to help them evaluate ALIM as an investment opportunity.
Alimera Appoints Maggie A. Pax to Its Board of DirectorsMaggie A. Pax Maggie A. Pax Appointed to Board of Directors of Alimera Sciences ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies. “Maggie’ |
Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of OphthalmologyATLANTA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg taken from the three-year, phase IV, real-world observational PALADIN study evaluating the long-term safety of ILUVIEN for patients with di |
Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call TranscriptAlimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript October 26, 2023 Alimera Sciences, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.41. Operator: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences Third Quarter 2022 [2023] (sic) Financial Results and Corporate Update Conference Call. [Operator […] |
Alimera Sciences Inc (ALIM) Reports Q3 2023 Financial ResultsRecord net revenue and significant decrease in net loss highlight the quarter |
Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue EstimatesAlimera Sciences (ALIM) delivered earnings and revenue surprises of 85.37% and 4.25%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
ALIM Price Returns
1-mo | 16.77% |
3-mo | -9.72% |
6-mo | 25.81% |
1-year | 119.10% |
3-year | -60.20% |
5-year | -75.47% |
YTD | -9.72% |
2023 | 59.41% |
2022 | -47.17% |
2021 | 21.56% |
2020 | -44.33% |
2019 | -29.62% |
Continue Researching ALIM
Want to do more research on Alimera Sciences Inc's stock and its price? Try the links below:Alimera Sciences Inc (ALIM) Stock Price | Nasdaq
Alimera Sciences Inc (ALIM) Stock Quote, History and News - Yahoo Finance
Alimera Sciences Inc (ALIM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...